Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Randomized Controlled Phase II Clinical Trial of Prostatectomy After Conversion Therapy With Second-generation Antiandrogen Agents Plus ADT in Patients With High-volume mHSPC(CONVERT-HB1)

NCT07268794 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07268794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07268794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Randomized Controlled Phase II Clinical Trial of Prostatectomy After Conversion Therapy With Second-generation Antiandrogen Agents Plus ADT in Patients With High-volume mHSPC(CONVERT-HB1)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
December 30, 2027
Enrollment
112 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer (mhspc), metastatic prostate cancer, prostate cancer (adenocarcinoma)